Allergan plc / ForSight VISION5, Inc.

Glaucoma / Ocular Hypertension

$980M Global bimatoprost market (2023 retrospective benchmark)

Disease Overview

Glaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP) that damages the optic nerve and causes irreversible vision loss. Primary open-angle glaucoma (POAG) is the most common form in the US, affecting ~2.7M adults 40+, with treatment overwhelmingly reliant on daily topical IOP-lowering eye drops — a regimen patients struggle to maintain.

Competitive Landscape

By 2016, glaucoma medical therapy was dominated by branded prostaglandin analogs and beta blockers — Allergan's own Lumigan (bimatoprost) and Restasis-adjacent eye care franchise, Pfizer's Xalatan/Xalacom (latanoprost), Alcon's Travatan Z (travoprost), and Akorn/Bausch generics. Sustained-release alternatives were a major emerging segment given that up to 50% of patients discontinue daily drops within 6 months. Allergan was already advancing Bimatoprost SR (a biodegradable intracameral implant), Tripligan, and the XEN gel stent — making the ForSight VISION5 deal a complementary, lower-invasiveness add to a 'dropless glaucoma' portfolio. ForSight's bimatoprost periocular ring is a preservative-free silicone-matrix insert containing 13 mg bimatoprost, placed under the eyelid in-office and releasing drug over 6 months at a descending dose. Phase 2 data published in Ophthalmology (Aug 2016) showed ~20% IOP reduction comparable to twice-daily timolol, with ~90% retention through 6 months. The deal followed competing efforts from Mati Therapeutics (punctal plug) and Glaukos (iStent procedural); the ring offered an extra-ocular, non-invasive option targeting mild-to-moderate disease.